Speaker
Renata Mikolajczak
(Polatom NCBJ)
Summary
The study evaluates the safety and efficacy of a new CCK2R-targeted radioligand therapy, [¹⁶¹Tb]Tb-CP04, in patients with advanced, inoperable medullary thyroid carcinoma (MTC). This approach may offer an effective and low-toxicity treatment option for this hard-to-treat cancer.
| Are you interested/eligible for the Young Session? | No, I am not eligible |
|---|
Author
Renata Mikolajczak
(Polatom NCBJ)
Co-authors
Prof.
Aldona Kowalska
(Collegium Medicum, Jan Kochanowski University in Kielce, Poland)
Prof.
Alicja Hubalewska-Dydejczyk
(Chair and Department of Endocrinology, Jagiellonian University Medical College, Krakow, Poland)
Prof.
Daria Handkiewicz-Junak
(Maria Skłodowska-Curie National Institute of Oncology, Gliwice Branch, Poland)
Dr
Izabela Cieszykowska
(National Centre for Nuclear Research, Radioisotope Centre POLATOM)
Dr
Marta Opalińska
(Chair and Department of Endocrinology, Jagiellonian University Medical College, Krakow, Poland)
Wioletta Lenda-Tracz
(Faculty of Health Sciences, Jagiellonian University Medical College, Krakow, Poland)
